The Latest Cardiac and Vascular News
Company marks 500th patient enrolled in the study and gains significant clinical experience with its next-generation CLAAS® AcuFORM™ Left Atrial Appendage Device NASHUA, N.H., April 2, 2025 /PRNewswire/ — Conformal Medical, Inc., a medical device company specializing in stroke prevention…
Abstract presentation will feature the first clinical use of the company’s CLAAS® AcuFORM™ Left Atrial Appendage Occlusion (LAAO) Device NASHUA, N.H., Jan. 16, 2025 /PRNewswire/ — Conformal Medical, Inc., today announced that the early results of its GLACE Study will be presented during…
Next-generation system to be highlighted during a technology innovation session and live case presentation by Professor Jens Erik Nielsen-Kudsk NASHUA, N.H., Oct. 22, 2024 /PRNewswire/ — Conformal Medical, Inc. announced today, the next-generation CLAAS® AcuFORM™ Left Atrial Appendage…
Study will assess the Company’s Next-Generation device under Intracardiac Echocardiography (ICE) imaging for Left Atrial Appendage Occlusion (LAAO) procedures. NASHUA, N.H., Oct. 1, 2024 /PRNewswire/ — Conformal Medical, Inc. today announced the initiation of the GLACE Study. This…
NASHUA, N.H. – March 13, 2024 – Conformal Medical, Inc. announced that the CLAAS® System was featured in a podium presentation at the Cardiovascular Research Technologies (CRT) 2024 conference. Dr. William Gray, Professor of Medicine, Thomas Jefferson University, System Chief, Cardiovascular Diseases at Main Line Health, and Co-Director Lankenau Heart Institute presented […]
The round was led by SPRIG Equity with participation from all major Series C investors NASHUA, N.H., June 5, 2023 /PRNewswire/ — Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion (LAAO) technology, today announced the successful completion of its Series D funding round, raising a total of $35 million. “SPRIG Equity is focused on enabling transformative medical technology companies to achieve meaningful milestones, and more importantly, […]
Data to be presented on February 3rd during a Spotlight Session at AF Symposium 2023 NASHUA, N.H., Jan. 31, 2023 /PRNewswire/ — Conformal Medical, Inc. announced today the presentation of the one-year data from the company’s initial left atrial appendage occlusion (LAAO) cases with its novel CLAAS® System in patients under conscious sedation without general anesthesia. […]
Seasoned Medical Device Executive, James Reinstein, Appointed as Chief Executive Officer NASHUA, N.H., Sept. 7, 2022 /PRNewswire/ — Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion (LAAO) technology, today announced the appointment of James Reinstein as President and Chief Executive Officer. With over three decades in the medical device industry, Reinstein has […]
Study to support U.S. FDA approval of the novel CLAAS® implant forleft atrial appendage occlusion (LAAO) and stroke prevention NASHUA, N.H., June 17, 2022 /PRNewswire/ — Conformal Medical, Inc., a medical device company developing next-generation LAAO technology, today announced the launch of the CONFORM pivotal trial with the enrollment of the first patients at two U.S. sites. The […]
U.S. and European feasibility studies demonstrate early success of novel conformable foam matrix implant for LAAC NASHUA, N.H., Oct. 15, 2020 /PRNewswire/ — Conformal Medical, Inc., a privately held medical device company developing next generation left atrial appendage closure (LAAC) technology, today announced positive clinical data from First-in-Human studies performed in the U.S. and Prague. […]
